Successful treatment of Pityriasis rubra pilaris with brodalumab

Response of pityriasis rubra pilaris to brodalumab after primary failure to ustekinumab

“…In our case, we obtained complete response after 10 weeks of treatment, with satisfactory relief of pruritus at 4 weeks. The efficacy and rapid onset of action of brodalumab in PRP has already been observed in two other patients, who achieved complete response after 8 weeks 4,5 …”

Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review

“…7 Ixekizumab accounts for the majority of cases (55.2%), followed by secukinumab (37.9%) and brodalumab (6.9%). 4,[8][9][10][11] Overall, they showed a CR of 68.7%. As regards anti-IL-12/23 agents, ustekinumab was used in 18.8% of examined PRP cases, showing a high effectiveness (CR of 80.7%) with low relapse rates at the withdrawal.…”

“…Anti‐TNF‐α, anti‐IL12/23, anti‐IL23, and anti‐IL17A have been employed so far up to 138 PRP patients (Table 1). 4‐15 Concerning TNF‐α inhibitors, infliximab is the most employed (26.8% of all PRP cases), followed by etanercept (17.4%) and adalimumab (14.5%) reaching a complete response (CR) in 54.3% of cases (Table 1). 2,3,5 As regards anti‐IL23, guselkumab has been employed in the treatment of two refractory cases of adult PRP, reaching a CR as early as 12 weeks, without any relapse 6 .…”

“…Anti‐IL17A agents are increasingly gaining a relevant therapeutic role in PRP (21%) 7 . Ixekizumab accounts for the majority of cases (55.2%), followed by secukinumab (37.9%) and brodalumab (6.9%) 4,8‐11 . Overall, they showed a CR of 68.7%.…”

Treatment of pityriasis rubra pilaris with risankizumab in two cases

“…The pivotal role of the IL-23/Th17 axis in some PRP patients has been emphasized recently [6] and results of previous case reports on IL-17 antagonists and the IL-12/23-directed ustekinumab in the treatment of PRP are promising [4,[7][8][9]. To our knowledge, it remains unclear whether IL-17 or IL-23 is the key cytokine in PRP.…”